Costanza Zanetti

Costanza Zanetti

Auto-generated profile, based on publicly available information

Costanza Zanetti

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in Blood
Verified
Journal Article
Closed access
PDF file
CZCostanza Zanetti
Costanza Zanetti
RKRahul Kumar
Rahul Kumar
JEJoscha Ender
Joscha Ender
PGParimala S. Godavarthy
Parimala S. Godavarthy
MHMark Hartmann
Mark Hartmann
DKDaniela S. Krause
Daniela S. Krause
B-cell acute lymphoblastic leukemia (B-ALL) occurs most commonly in children, whereas chronic myeloid leukemia is more frequent in adults. The myeloid bias of hematopoiesis in elderly individuals has been considered causative, but the age of the bone marrow microenvironment (BMM) may be contributory. Using various murine models of B-ALL in young vs old mice, we recapitulated B-ALL preponderance in children vs adults. We showed differential effects of young vs old BM macrophages on B-ALL cell function. Molecular profiling using RNA- and ATAC-sequencing revealed pronounced differences in young vs old BMM-derived macrophages and enrichment for gene sets associated with inflammation. In concordance with the role of C-X-C motif chemokine (CXCL) 13 for disease-associated B-cell chemoattraction, we found CXCL13 to be highly expressed in young macrophages on a translational compared with a transcriptional level. Inhibition of CXCL13 in BM macrophages impaired leukemia cell migration and decreased the proliferation of cocultured B-ALL cells, whereas recombinant CXCL13 increased pAKT and B-ALL cell expansion. Pretreatment of B-ALL–initiating cells with CXCL13 accelerated B-ALL progression. Deficiency of Cxcr5, the receptor for CXCL13, on B-ALL–initiating cells prolonged murine survival, whereas high expression of CXCR5 in pediatric B-ALL may predict central nervous system relapse. CXCL13 staining was increased in bone sections from pediatric compared with adult patients with B-ALL. Taken together, our study shows that the age of the BMM and, in particular, BM macrophages influence the leukemia phenotype. The CXCR5-CXCL13 axis may act as prognostic marker and an attractive novel target for the treatment of B-ALL.

31 March 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
CKChristina Karantanou
Christina Karantanou
VMValentina R. Minciacchi
Valentina R. Minciacchi
RKRahul Kumar
Rahul Kumar
CZCostanza Zanetti
Costanza Zanetti
JBJimena Bravo
Jimena Bravo
DKDaniela S. Krause
Daniela S. Krause
Leukemia cells reciprocally interact with their surrounding bone marrow microenvironment (BMM), rendering it hospitable to leukemia cell survival, for instance through the release of small extracellular vesicles (sEVs). In contrast, we show here that BMM deficiency of pleckstrin homology domain family M member 1 (PLEKHM1), which serves as a hub between fusion and secretion of intracellular vesicles and is important for vesicular secretion in osteoclasts, accelerates murine BCR-ABL1+ B-cell acute lymphoblastic leukemia (B-ALL) via regulation of the cargo of sEVs released by BMM-derived mesenchymal stromal cells (MSCs). PLEKHM1-deficient MSCs and their sEVs carry increased amounts of syntenin and syndecan-1, resulting in a more immature B-cell phenotype and an increased number/function of leukemia-initiating cells (LICs) via focal adhesion kinase and AKT signaling in B-ALL cells. Ex vivo pretreatment of LICs with sEVs derived from PLEKHM1-deficient MSCs led to a strong trend toward acceleration of murine and human BCR-ABL1+ B-ALL. In turn, inflammatory mediators such as recombinant or B-ALL cell–derived tumor necrosis factor α or interleukin-1β condition murine and human MSCs in vitro, decreasing PLEKHM1, while increasing syntenin and syndecan-1 in MSCs, thereby perpetuating the sEV-associated circuit. Consistently, human trephine biopsies of patients with B-ALL showed a reduced percentage of PLEKHM1+ MSCs. In summary, our data reveal an important role of BMM-derived sEVs for driving specifically BCR-ABL1+ B-ALL, possibly contributing to its worse prognosis compared with BCR-ABL1− B-ALL, and suggest that secretion of inflammatory cytokines by cancer cells in general may similarly modulate the tumor microenvironment.

6 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
RPRaquel S. Pereira
Raquel S. Pereira
RKRahul Kumar
Rahul Kumar
ACAlessia Cais
Alessia Cais
LPLara Paulini
Lara Paulini
AKAlisa Kahler
Alisa Kahler
DKDaniela S. Krause
Daniela S. Krause
Haematopoietic stem cells (HSC) reside in the bone marrow microenvironment (BMM), where they respond to extracellular calcium [eCa2+] via the G-protein coupled calcium-sensing receptor (CaSR). Here we show that a calcium gradient exists in this BMM, and that [eCa2+] and response to [eCa2+] differ between leukaemias. CaSR influences the location of MLL-AF9+ acute myeloid leukaemia (AML) cells within this niche and differentially impacts MLL-AF9+ AML versus BCR-ABL1+ leukaemias. Deficiency of CaSR reduces AML leukaemic stem cells (LSC) 6.5-fold. CaSR interacts with filamin A, a crosslinker of actin filaments, affects stemness-associated factors and modulates pERK, β-catenin and c-MYC signaling and intracellular levels of [Ca2+] in MLL-AF9+ AML cells. Combination treatment of cytarabine plus CaSR-inhibition in various models may be superior to cytarabine alone. Our studies suggest CaSR to be a differential and targetable factor in leukaemia progression influencing self-renewal of AML LSC via [eCa2+] cues from the BMM.

12 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAngelique Schönefeld
Angelique Schönefeld
CZCostanza Zanetti
Costanza Zanetti
ESEric C. Schmitt
Eric C. Schmitt
KWKevin Woods
Kevin Woods
AWAshley Westerback
Ashley Westerback
BGBorhane Guezguez
Borhane Guezguez
Epigenetic dysregulation is a hallmark of Acute Myeloid Leukemia (AML), with mutations in DNA Methyltransferases (e.g., DNMT3A) being frequent and promising therapeutic targets. DNMTs form complexes with Histone Methyltransferases (HMTs), driving gene silencing loop via chromatin methylation crosstalk. However, potential connections between this DNMTs/HMTs cooperative activity and oncogenic requirements across the AML mutational spectrum remain poorly understood. Here, we demonstrate that AMLs carrying DNMT3A and Nucleophosmin (NPM1) mutations exhibit a specific epigenetic vulnerability toward a complex formed by DNMTs and G9a, a specific histone H3 Lysine 9 Methyltransferase (H3K9-HMT). Dual inhibition of DNMT/G9a restores differentiation, reduces tumor growth, and spares healthy progenitors compared to standard hypomethylating agents. Mechanistically, DNMT/G9a regulates NPM1 stability, inhibits HOXA9/MEIS1 activity, and triggers interferons (IFN) response via viral mimicry pathways by modulating hypermethylated retrotransposons. Collectively, our data unravel specific epigenetic vulnerabilities within the complex AML mutational landscape and provide a compelling rationale for the design of personalized epigenetic therapies with enhanced efficacy and safer clinical outcomes.

29 November 2018 in Blood
Verified
Journal Article
Open access
DVDivij Verma
Divij Verma
CZCostanza Zanetti
Costanza Zanetti
MFMichaela Fontenay
Michaela Fontenay
DKDaniela S. Krause
Daniela S. Krause
Interactions with the bone marrow microenvironment (BMM) influence the pathophysiology of hematological malignancies. Reciprocally, hematological malignancies remodel the BMM in order to render it more hospitable for malignant progression. Hypothesizing that different leukemias differentially remodel stroma cells in the BMM, we tested differences in the expression of various genes in sorted osteoblastic cells from mice with B-cell acute lymphoblastic (B-ALL), acute myeloid (AML) or chronic myeloid leukemia (CML) or control mice by microarray. This revealed a high expression of various proteases, especially matrix metalloproteinase-9 (MMP-9), in osteoblastic cells isolated from mice with B-ALL. MMP-9 had previously been shown to be produced by leukemia cells. To investigate the physiological relevance of BMM-derived MMP-9 for the progression of B-ALL, we employed the well-established retroviral transduction/transplantation model of BCR-ABL1-dependent B-ALL in MMP-9-deficient or wildtype mice. Deficiency of MMP-9 in the BMM prolonged the survival of mice with B-ALL compared to wildtype mice. Secondary transplantation of bone marrow from wildtype versus MMP-9 knockout (KO) mice with B-ALL led to a significant prolongation of survival of recipients of B-ALL bone marrow from MMP-9 KO mice, suggesting that leukemia-initiating cells are reduced in a MMP-9 KO BMM. In addition, we observed reduced invasion of B-ALL cells into different organs such as spleen, meninges, lungs and liver, which likely underlies the observed prolongation of survival, as well as the reduced degradation of extracellular matrix (ECM) proteins such as laminin and fibronectin in the BMM of MMP-9 deficient mice. Mechanistically, using various in vivo and in vitro assays, as well as mice deficient for the receptor for tumor necrosis factor-α (TNF-α) we have demonstrated that B-ALL cells induce MMP-9-expression in niche cells, such as mesenchymal stem cells (MSC), via a release of high amounts of TNF-α, both in the murine and the human setting. TNF-α-dependent induction of MMP-9 in MSC was mediated via TNF-receptor-1, followed by activation of the downstream target nuclear factor kappa B (NF-kB). Consistently, transplantation of B-ALL-initiating cells, in which TNF-α had been knocked down, led to a significant prolongation of survival in B-ALL mice. Testing whether treatment of mice with B-ALL with an inhibitor of MMP-9 may prolong survival compared to vehicle-treated mice, we indeed found decreased degradation of ECM proteins in the BMM, a decreased leukemia burden in peripheral blood and a significant prolongation of survival. In addition, we observed reduced minimal residual disease in the bone marrow of mice with B-ALL when the mice had been treated with cytarabine and the MMP-9 inhibitor compared to mice treated with cytarabine alone. Experiments on testing the effect of MMP-9 inhibitor treatment on human B-ALL cells in a xenotransplantation model are currently ongoing. In summary, we have demonstrated the role of BMM-derived MMP-9 for B-ALL progression. B-ALL cells self-reinforce the BMM by inducing the production of MMP-9 via the release of TNF-α. Increased production of MMP-9 from the BMM promotes B-ALL progression via increased invasion of leukemic cells into different organs. Our data suggest, that inhibition of MMP-9 may be a feasible strategy as an adjunct to existing therapies.